In January, Koninklijke Philips NV (NYSE:PHG) announced that it would stop selling new CPAP or BiPAP sleep therapy devices or other respiratory care devices in the U.S. until the consent decree’s requirements are met.
Internationally, Philips Respironics will maintain its provision of new sleep and respiratory care devices, along with associated accessories, consumables, replacement parts, and services, subject to specific conditions.
William Blair writes that Inogen Inc (NASDAQ:INGN) has a significant opportunity to regain a substantial portion of the forfeited market share.
The analysis suggests that Respironics was the second-largest player in the market, with an estimated 15%-25% share. William Blair expects Inogen …
Full story available on Benzinga.com